Search
Somatostatin deficits in olfactory systems : early biomarkers of Alzheimer disease – SOMADOLF
Somatostatin (SRIF) is a widely expressed neuropeptide in the brain involved in neuroendocrine, cognitive and sensory functions Hippocampal and cortical somatostatinergic levels are consistently reduced in Alzheimer’s disease (AD), being clearly associated with cognitive impairments. Recently, a pri
NMR-spectroscopic characterization of the conformational changes of the Alzheimer-associated protein Tau induced by phosphorylation – TAU-STRUCT
Our aim is to develop a molecular ensemble description of Tau that combines and reflects multiple complementary conformationally-dependent experimental parameters. We will use this description to examine the transition from apparent normality into the diseased state of Tau. In Alzheimer's disease, T
Cellular, molecular and systems-level mechanisms underlying the establishment of a brain cognitive reserve in a mouse model of Alzheimer’s disease – CoRehAlz
The “cognitive reserve” model suggests that individuals with greater brain reserve capacity (i.e. with higher level of education or occupational attainment) may develop resilience to neurodegenerative damage and optimize behavioral abilities through differential recruitment of neural networks and/or
Synaptic deficits and neuroinflammation in mouse models of Alzheimr's disease – SynflAD
Intracellular accumulation of neurofibrillary tangles and senile plaques formed by the extracellular deposit of cerebral amyloid-ß (Aß) peptide oligomers are the classical pathological hallmarks of Alzheimer's disease (AD) and lead ultimately to neuronal cell death. However, it has become clear more
Netrin-1 as a ligand for APP receptor: molecular mechanism and implication in Alzheimer disease – APPNET
Despite the extensive research on Alzheimer's disease (AD) since its first description in 1907-including the sequencing of Aß peptide in 1984 and cloning of its precursor, APP (ß-amyloid precursor protein), in 1987-little is known about potential ligand interactions with APP, or about any associated
Cognitive REServe and Clinical ENDOphenotypes – CRESCENDO
Cognitive reserve (CR) has been postulated to mediate the relationship between age- or Alzheimer’s disease (AD)-related pathology and the clinical impact of that pathology. However little is known about the neural implementation that may underlie CR. Based on the hypothesis that CR can attenuate t
Deciphering the role of nuclear Tau and the Influence of ABeta oligomers. in neurons under physiological and stress conditions. – EPITAUDNA
Tau protein, a key actor in Alzheimer’s disease, is mainly known as a cytosolic protein associated to microtubules. However, Tau is also present in neuronal nuclei where its function has remained unknown. To decipher the different functions of Tau is essential to highlight new therapeuthical targets
Cell therapy and Alzheimer’s disease : therapeutic potential and mechanisms action of human olfactory nasal stem cells – AD HOC
Background At present, Alzheimer’s disease (AD) affects 7 million European people. U.S. society spends at least $100 billion a year on AD and it is expected that AD will cost $500 billion a year by 2020. In addition to memory loss, AD is characterized by an extensive cell death. Worldwide, we are o
Molecular imaging of nicotinic alpha7 receptors in Alzheimer's disease – MInAlpha7
Alzheimer’s disease (AD) is the most frequent progressive neurodegenerative disease representing the major cause of dementia in elderly subject. With 860000 people affected in France, it is a major public health problem. The diagnosis of AD is currently based on clinical criteria. The certitude diag